Isocitrate dehydrogenase 1 (IDH1) mutations have been discovered to be frequent and highly conserved in secondary glioblastoma multiforme and lower-grade gliomas. Although IDH1 mutations confer a unique genotype that has been associated with a favorable prognosis, the role of the mutated IDH1 enzyme and its metabolites in tumor initiation and maintenance remains unresolved. However, given that IDH1 mutations are homogeneously expressed and are limited solely to tumor tissue, targeting this mutation could potentially yield novel treatment strategies for patients with glioblastoma multiforme.
Abbreviations used in this paper:αKG = alpha-ketoglutarate; GBM = glioblastoma multiforme; HIF-1α = hypoxia-inducing factor–1α; IDH1 = isocitrate dehydrogenase 1; PCV = procarbazine, lomustine, and vincristine; TMZ = temozolomide; 2HG = 2-hydroxyglutarate.
Address correspondence to: John H. Sampson, M.D., Ph.D., Duke Brain Tumor Immunotherapy Program, Preston Robert Tisch Brain Tumor Center, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Box 3050, Durham, North Carolina 27710. email: firstname.lastname@example.org.
Please include this information when citing this paper: published online April 12, 2013; DOI: 10.3171/2013.3.JNS122282.
AmaryMFBacsiKMaggianiFDamatoSHalaiDBerishaF: IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol224:334–3432011
AndronesiOCKimGSGerstnerEBatchelorTTzikaAAFantinVR: Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med4:116ra42012
BorthakurGHuangXKantarjianHFaderlSRavandiFFerrajoliA: Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma51:73–782010
CapperDReussDSchittenhelmJHartmannCBremerJSahmF: Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol121:241–2522011
van den BentMJDubbinkHJMarieYBrandesAATaphoornMJWesselingP: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res16:1597–16042010